¼¼°èÀÇ ÀÇ·á ¹Ì»ý¹° °Ë»ç ±â¼ú ½ÃÀå
Medical Microbiology Testing Technologies
»óǰÄÚµå : 1760887
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 173 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,106,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,320,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

ÀÇ·á ¹Ì»ý¹° °Ë»ç ±â¼ú ¼¼°è ½ÃÀåÀº 2030³â±îÁö 37¾ï ´Þ·¯¿¡ µµ´Þ

2024³â¿¡ 29¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ÀÇ·á ¹Ì»ý¹° °Ë»ç ±â¼ú ¼¼°è ½ÃÀåÀº 2024-2030³âÀÇ ºÐ¼® ±â°£¿¡ CAGR 4.1%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 37¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀΠȣÈí±âÁúȯÀº CAGR 4.9%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 14¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ½Å°æÁúȯ ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 3.6%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 7¾ï 4,710¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 7.1%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ÀÇ·á ¹Ì»ý¹° °Ë»ç ±â¼ú ½ÃÀåÀº 2024³â¿¡ 7¾ï 4,710¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³â°£ CAGR 7.1%·Î 2030³â±îÁö 8¾ï 6,470¸¸ ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 1.3%¿Í 3.1%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.1%¸¦ º¸ÀÏ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ ÀÇ·á ¹Ì»ý¹° °Ë»ç ±â¼ú ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

ÀÇ·á ¹Ì»ý¹° °Ë»ç ±â¼úÀÌ ÇコÄɾ ÇʼöÀûÀÎ ÀÌÀ¯´Â ¹«¾ùÀϱî?

ÀÇ·á ¹Ì»ý¹° °Ë»ç ±â¼úÀº °¨¿° ¿äÀÎÀ» È®ÀÎÇϰí, Ä¡·á¹ýÀ» °áÁ¤Çϰí, Áúº´ ¹ß»ýÀ» ¿¹¹æÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀº ¼¼±Õ, ¹ÙÀÌ·¯½º, Áø±Õ °¨¿°ÀÇ Áø´Ü¿¡ »ç¿ëµÇ¸ç, È£Èí±â °¨¿°¿¡¼­ º´¿ø ³» °¨¿°¿¡ À̸£±â±îÁö ´Ù¾çÇÑ Áõ»ó °ü¸®¿¡ ÇʼöÀûÀÔ´Ï´Ù. Ç×»ýÁ¦ ³»¼º ¹× ½ÅÁ¾ °¨¿°¿¡ ´ëÇÑ ¿ì·Á°¡ Ä¿Áö¸é¼­ ½Å¼ÓÇϰí Á¤È®ÇÑ ¹Ì»ý¹° °Ë»ç°¡ ÀÇ·á°èÀÇ ÃÖ¿ì¼± °úÁ¦·Î ¶°¿À¸£°í ÀÖ½À´Ï´Ù. ÀÇ·á¿ë ¹Ì»ý¹° °Ë»ç´Â Áúº´ °¨¿°À» ÁÙÀÌ°í °øÁß º¸°Ç ÀÌ´Ï¼ÅÆ¼ºê¸¦ Áö¿øÇÏ´Â µ¥ ÀÖ¾î ±âº»ÀûÀÎ ¿ªÇÒÀ» ÇÕ´Ï´Ù.

¾î¶² Çõ½ÅÀÌ ÀÇ·á¿ë ¹Ì»ý¹° °Ë»ç¸¦ ÃËÁøÇϰí Àִ°¡?

ºÐÀÚÁø´ÜÇÐ, ÁßÇÕÈ¿¼Ò¿¬¼â¹ÝÀÀ(PCR) ±â¼ú, ÀÚµ¿È­µÈ °Ë»ç Ç÷§ÆûÀÇ ±â¼ú ¹ßÀüÀº ÀÇ·á ¹Ì»ý¹°Çп¡ Çõ¸íÀ» ÀÏÀ¸Ä×½À´Ï´Ù. ºÐÀÚÁø´ÜÇÐÀº À¯ÀüÀÚ ¼öÁØ¿¡¼­ º´¿ø±ÕÀ» ½Å¼ÓÇÏ°Ô °ËÃâÇÒ ¼ö ÀÖÀ¸¸ç, ±âÁ¸ ¹è¾ç¹ý¿¡ ºñÇØ ¸î ½Ã°£ À̳»¿¡ °á°ú¸¦ Á¦°øÇÕ´Ï´Ù. ½Ç½Ã°£ PCR°ú °°Àº PCRÀÇ ¹ßÀüÀº °Ë»çÀÇ ¹Î°¨µµ¿Í Á¤È®µµ¸¦ ³ô¿© Á¶±â Áø´Ü°ú Ç¥Àû Ä¡·á¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ÀÚµ¿È­µÈ °Ë»ç Ç÷§Æû°ú ·¦¿ÂĨ ±â¼úÀº °Ë»ç ÇÁ·Î¼¼½º¸¦ °£¼ÒÈ­ÇÏ¿© ºü¸¥ ³³±â¿Í °Ë»ç·® Áõ°¡¸¦ °¡´ÉÇÏ°Ô Çß½À´Ï´Ù. ÀÌ·¯ÇÑ Çõ½ÅÀ» ÅëÇØ ¹Ì»ý¹°ÇÐ °Ë»ç´Â ´õ¿í ½Å¼ÓÇϰí Á¤È®µµ°¡ ³ô¾ÆÁ³À¸¸ç, ¸ðµç ÀÇ·á ½Ã¼³¿¡¼­ ½±°Ô ÀÌ¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.

¹Ì»ý¹° °Ë»ç ±â¼ú Ȱ¿ëÀ» ¼±µµÇϰí ÀÖ´Â ÀÇ·á ºÐ¾ß´Â?

°í±Þ ¹Ì»ý¹° °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä°¡ °¡Àå ³ôÀº °÷Àº º´¿ø °Ë»ç½Ç, °øÁߺ¸°Ç±¹, ¿Ü·¡Áø·á¼ÒÀÔ´Ï´Ù. º´¿ø °Ë»ç½Ç¿¡¼­´Â °¨¿°º´ Áø´Ü, Ç×»ýÁ¦ »ç¿ë Áöµµ, °¨¿° °ü¸®¸¦ À§ÇØ ¹Ì»ý¹° °Ë»ç¸¦ Ȱ¿ëÇϰí ÀÖ½À´Ï´Ù. °øÁß º¸°Ç ±â°üÀº Àü¿°º´ ¹ß»ýÀ» ÃßÀûÇÏ°í °øÁß º¸°Ç ´ëÀÀ¿¡ ÇʼöÀûÀÎ µ¥ÀÌÅ͸¦ Á¦°øÇϱâ À§ÇØ ÀÌ·¯ÇÑ ±â¼úÀ» »ç¿ëÇÕ´Ï´Ù. ¿Ü·¡ Áø·á¼Ò¿¡¼­´Â ÀϹÝÀûÀÎ °¨¿°¼º Áúȯ¿¡ ´ëÇÑ ½Å¼ÓÇÑ Áø´Ü µµ±¸ÀÇ ÇýÅÃÀ» ´©¸®°í ÀÖÀ¸¸ç, À̸¦ ÅëÇØ ½Å¼ÓÇÑ Ä¡·á°¡ °¡´ÉÇØÁ³½À´Ï´Ù. ÀÌ·¯ÇÑ ÀÇ·á ÇöÀå¿¡¼­ÀÇ ±¤¹üÀ§ÇÑ Ã¤ÅÃÀº °øÁß º¸°Ç°ú ȯÀÚ ¾ÈÀüÀ» À¯ÁöÇÏ´Â µ¥ ÀÖ¾î ¹Ì»ý¹°ÇÐ °Ë»çÀÇ Áß¿äÇÑ ¿ªÇÒÀ» °­Á¶Çϰí ÀÖ½À´Ï´Ù.

ÀÇ·á ¹Ì»ý¹° °Ë»ç ±â¼ú ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµË´Ï´Ù.

ÀÇ·á¿ë ¹Ì»ý¹° °Ë»ç ±â¼ú ½ÃÀåÀÇ ¼ºÀåÀº °¨¿°¼º Áúȯ Áõ°¡, ºÐÀÚÁø´ÜÀÇ ¹ßÀü, Ç×»ýÁ¦ ³»¼º¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡ µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î °¨¿°¼º ÁúȯÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ½Å¼ÓÇϰí Á¤È®ÇÑ °Ë»ç ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ƯÈ÷ PCR°ú ÀÚµ¿È­ÀÇ ±â¼ú ¹ßÀüÀº Áø´ÜÀÇ Á¤È®¼º°ú ¼Óµµ¸¦ Çâ»ó½ÃÄÑ ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü¿¡°Ô ÇʼöÀûÀÎ ±â¼ú·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Ç×»ýÁ¦ ³»¼º¿¡ ´ëÀÀÇϱâ À§ÇÑ °øÁߺ¸°Ç ÀÌ´Ï¼ÅÆ¼ºê´Â ¹Ì»ý¹° °Ë»çÀÇ Á߿伺À» °­Á¶ÇÏ°í ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϸç ÷´Ü Áø´Ü ±â¼úÀÇ Ã¤ÅÃÀ» µ½°í ÀÖ½À´Ï´Ù.

ºÎ¹®

¿ëµµ(Áø´Ü, Ä¡·á ¸ð´ÏÅ͸µ);ÃÖÁ¾ ¿ëµµ(º´¿ø ½ÇÇè½Ç, º´¸® ½ÇÇè½Ç, ¿¬±¸±â°ü);ÀûÀÀÁõ(È£Èí±âÁúȯ, ½Å°æÁúȯ, °¨¿°Áõ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹(ÃÑ 41°³»ç)

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Medical Microbiology Testing Technologies Market to Reach US$3.7 Billion by 2030

The global market for Medical Microbiology Testing Technologies estimated at US$2.9 Billion in the year 2024, is expected to reach US$3.7 Billion by 2030, growing at a CAGR of 4.1% over the analysis period 2024-2030. Respiratory Diseases, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Neurological Diseases segment is estimated at 3.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$747.1 Million While China is Forecast to Grow at 7.1% CAGR

The Medical Microbiology Testing Technologies market in the U.S. is estimated at US$747.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$864.7 Million by the year 2030 trailing a CAGR of 7.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 3.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.1% CAGR.

Global Medical Microbiology Testing Technologies Market - Key Trends & Drivers Summarized

Why Are Medical Microbiology Testing Technologies Vital in Healthcare?

Medical microbiology testing technologies are crucial for identifying infectious agents, guiding treatment decisions, and preventing disease outbreaks. These technologies are used to diagnose bacterial, viral, and fungal infections, essential for managing conditions ranging from respiratory infections to hospital-acquired infections. With rising concerns over antibiotic resistance and emerging infectious diseases, rapid and accurate microbiology testing has become a top priority in healthcare. Medical microbiology testing plays a fundamental role in reducing disease transmission and supporting public health initiatives.

What Innovations Are Driving Medical Microbiology Testing?

Technological advancements in molecular diagnostics, polymerase chain reaction (PCR) technology, and automated testing platforms have revolutionized medical microbiology. Molecular diagnostics enable rapid detection of pathogens at a genetic level, providing results within hours compared to traditional culture methods. PCR advancements, such as real-time PCR, enhance test sensitivity and accuracy, allowing for earlier diagnosis and targeted treatment. Automated testing platforms and lab-on-a-chip technologies have streamlined testing processes, enabling faster turnaround times and higher testing volumes. These innovations have made microbiology testing faster, more precise, and accessible across healthcare facilities.

Which Medical Sectors Are Leading the Use of Microbiology Testing Technologies?

The demand for advanced microbiology testing is highest in hospital laboratories, public health departments, and outpatient clinics. Hospital laboratories rely on microbiology testing for diagnosing infections, guiding antibiotic use, and managing infection control. Public health agencies use these technologies to track infectious disease outbreaks, providing essential data for public health responses. Outpatient clinics benefit from rapid diagnostic tools for common infections, allowing for prompt treatment. This widespread adoption across healthcare settings highlights the critical role of microbiology testing in maintaining public health and patient safety.

The Growth in the Medical Microbiology Testing Technologies Market Is Driven by Several Factors

The growth in the medical microbiology testing technologies market is driven by several factors, including the rise in infectious disease prevalence, advancements in molecular diagnostics, and increasing awareness of antibiotic resistance. The global increase in infectious diseases has heightened demand for fast, accurate testing solutions. Technological advancements, especially in PCR and automation, have enhanced diagnostic accuracy and speed, making these technologies indispensable for healthcare providers. Furthermore, public health initiatives aimed at combating antibiotic resistance have underscored the importance of microbiology testing, driving market growth and supporting the adoption of advanced diagnostic technologies.

SCOPE OF STUDY:

The report analyzes the Medical Microbiology Testing Technologies market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Application (Diagnostic, Treatment Monitoring); End-Use (Hospital Labs, Pathology Labs, Research Institutes); Indication (Respiratory Diseases, Neurological Diseases, Infectious Diseases)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â